Recent developments of neuroprotective agents for degenerative retinal disorders  

作　　者：Kepeng Ou Youjian Li Ling Liu Hua Li Katherine Cox Jiahui Wu Jian Liu Andrew D.Dick 

机构地区：[1]College of Pharmacy,National&Local Joint Engineering Research Center of Targeted and Innovative Therapeutics,IATTI,Chongqing University of Arts and Sciences,Chongqing,China [2]Translational Health Sciences,Bristol Medical School,University of Bristol,Bristol,UK [3]Department of Ophthalmology,Yongchuan Hospital,Chongqing Medical University,Chongqing,China [4]Department of Ophthalmology,Shanghai General Hospital(Shanghai First People’s Hospital),Shanghai Jiao Tong University School of Medicine,Shanghai,China [5]Institute of Ophthalmology,University College London,London,UK [6]National Institute for Health Research Biomedical Research Centre,Moorfields Eye Hospital,London,UK

出　　处：《Neural Regeneration Research》2022年第9期1919-1928,共10页中国神经再生研究（英文版）

摘　　要：Retinal degeneration is a debilitating ocular complication characterized by the progressive loss of photoreceptors and other retinal neurons,which are caused by a group of retinal diseases affecting various age groups,and increasingly prevalent in the elderly.Age-related macular degeneration,diabetic retinopathy and glaucoma are among the most common complex degenerative retinal disorders,posing significant public health problems worldwide largely due to the aging society and the lack of effective therapeutics.Whilst pathoetiologies vary,if left untreated,loss of retinal neurons can result in an acquired degeneration and ultimately severe visual impairment.Irrespective of underlined etiology,loss of neurons and supporting cells including retinal pigment epithelium,microvascular endothelium,and glia,converges as the common endpoint of retinal degeneration and therefore discovery or repurposing of therapies to protect retinal neurons directly or indirectly are under intensive investigation.This review overviews recent developments of potential neuroprotectants including neuropeptides,exosomes,mitochondrial-derived peptides,complement inhibitors,senolytics,autophagy enhancers and antioxidants either still experimentally or in clinical trials.Effective treatments that possess direct or indirect neuroprotective properties would significantly lift the burden of visual handicap.

关 键 词：ANTIOXIDANTS autophagy enhancers complement inhibitors EXOSOMES NEUROPEPTIDES neuroprotective agents retinal degeneration senolytics 

分 类 号：R774.13[医药卫生—眼科]